S. Beslija

1.7k total citations · 1 hit paper
49 papers, 876 citations indexed

About

S. Beslija is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S. Beslija has authored 49 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in S. Beslija's work include Cancer Treatment and Pharmacology (24 papers), Advanced Breast Cancer Therapies (13 papers) and Breast Cancer Treatment Studies (13 papers). S. Beslija is often cited by papers focused on Cancer Treatment and Pharmacology (24 papers), Advanced Breast Cancer Therapies (13 papers) and Breast Cancer Treatment Studies (13 papers). S. Beslija collaborates with scholars based in Bosnia and Herzegovina, Austria and Hungary. S. Beslija's co-authors include Helen Barraclough, Juan Carlos Alcedo, Mauro Orlando, Luís Casanova, Shahid Hameed, Alfonso Dueñas‐González, Firuza D. Patel, Juan José Zarbá, Pittayapoom Pattaranutaporn and Julie M. Blair and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

S. Beslija

45 papers receiving 856 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

2011 349 citations Alfonso Dueñas‐González, Juan José Zarbá et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Beslija Bosnia and Herzegovina	14	430	343	237	196	182	49	876
Mivael Olivera Peru	10	481 1.1×	385 1.1×	232 1.0×	244 1.2×	78 0.4×	31	852
Corinne Doll Canada	20	401 0.9×	355 1.0×	388 1.6×	191 1.0×	161 0.9×	70	1.1k
Vincent Castonguay Canada	11	563 1.3×	415 1.2×	239 1.0×	250 1.3×	106 0.6×	43	1.0k
D. Rollo Italy	3	260 0.6×	507 1.5×	212 0.9×	314 1.6×	138 0.8×	5	892
Roberta Tana Italy	17	183 0.4×	399 1.2×	205 0.9×	195 1.0×	82 0.5×	22	803
Beant S. Gill United States	17	279 0.6×	481 1.4×	378 1.6×	196 1.0×	75 0.4×	34	1.1k
Sileny Han Belgium	23	1.1k 2.5×	279 0.8×	136 0.6×	463 2.4×	196 1.1×	73	1.5k
Noriko Seki Japan	17	332 0.8×	449 1.3×	108 0.5×	124 0.6×	145 0.8×	39	892
D. Smaniotto Italy	19	361 0.8×	541 1.6×	486 2.1×	302 1.5×	62 0.3×	50	1.0k
Firuza D. Patel India	17	195 0.5×	719 2.1×	546 2.3×	318 1.6×	112 0.6×	49	1.2k

Countries citing papers authored by S. Beslija

Since Specialization

Citations

This map shows the geographic impact of S. Beslija's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Beslija with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Beslija more than expected).

Fields of papers citing papers by S. Beslija

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Beslija. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Beslija. The network helps show where S. Beslija may publish in the future.

Co-authorship network of co-authors of S. Beslija

This figure shows the co-authorship network connecting the top 25 collaborators of S. Beslija. A scholar is included among the top collaborators of S. Beslija based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Beslija. S. Beslija is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cerić, Timur, et al.. (2025). Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study. Biomolecules and Biomedicine. 26(1). 144–149.

Beslija, S., et al.. (2023). Statistical Modeling of Relations Between PET/CT Parameters and CEA in Recurrent and Metastatic Colorectal Cancer. Acta Informatica Medica. 31(2). 115–115. 1 indexed citations

Cerić, Timur, et al.. (2022). The Oncology Association of Bosnia and Herzegovina's Recommendations for Fertility Preservation in Oncologic Patients. Bosnian Journal of Basic Medical Sciences. 22(5). 646–650. 1 indexed citations

Sokolović, Emir, et al.. (2020). The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer. Acta Medica Academica. 49(1). 1–1. 8 indexed citations

Beslija, S., et al.. (2019). Colorectal Cancer Surgical Treatment, our Experience. Medical Archives. 73(6). 412–412. 47 indexed citations

Beslija, S., et al.. (2018). Better non-invasive endoscopic procedure: endoscopic ultrasound or magnetic resonance cholangiopancreatography?. Medicinski Glasnik. 16(1). 77–82. 4 indexed citations

Bilalović, Nurija, et al.. (2018). A clinicopathologic study of invasive apocrine carcinoma of the breast: A single-center experience. The Breast Journal. 24(6). 1105–1108. 11 indexed citations

Zielinski, Christoph, István Láng, Moshe Inbar, et al.. (2016). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. The Lancet Oncology. 17(9). 1230–1239. 42 indexed citations

Zielinski, Christoph, István Láng, S. Beslija, et al.. (2015). Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer. 114(2). 163–170. 21 indexed citations

10.

Brodowicz, Thomas, István Láng, Zsuzsanna Kahán, et al.. (2014). Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer. 111(11). 2051–2057. 24 indexed citations

11.

Inbar, Moshe, István Láng, Zsuzsanna Kahán, et al.. (2013). Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT.. Journal of Clinical Oncology. 31(15_suppl). 1040–1040. 4 indexed citations

12.

Inbar, Moshe, Zsuzsanna Kahán, Richard Greil, et al.. (2012). Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer. 48(17). 3140–3149. 16 indexed citations

13.

Beslija, S., et al.. (2012). Randomized phase II study of induction chemotherapy with gemcitabine plus cisplatin followed by sequential radiotherapy versus radiotherapy alone in patients with stage III non-small cell lung cancer.. PubMed. 10(3). 347–55.

14.

Zielinski, Christoph, István Láng, Moshe Inbar, et al.. (2012). First Efficacy Results From the Turandot Phase III Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MBC). Annals of Oncology. 23. ix116–ix116. 6 indexed citations

15.

Dueñas‐González, Alfonso, Juan José Zarbá, Firuza D. Patel, et al.. (2011). Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix. Journal of Clinical Oncology. 29(13). 1678–1685. 349 indexed citations breakdown →

16.

Dueñas‐González, Alfonso, Juan José Zarbá, Juan Carlos Alcedo, et al.. (2009). G3 A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. European Journal of Cancer Supplements. 7(3). 7–7. 1 indexed citations

17.

Ciuleanu, Tudor–Eliade, G. Kurteva, Janja Ocvirk, et al.. (2008). A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 26(15_suppl). 4032–4032. 9 indexed citations

18.

Beslija, S., et al.. (2007). How to make the best use of limited resources in breast cancer treatment--experiences in Bosnia & Herzegovina.. PubMed. 11(1). 21–9. 4 indexed citations

19.

Köse, Mehmet Faruk, Jozef Šufliarský, S. Beslija, et al.. (2004). A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecologic Oncology. 96(2). 374–380. 25 indexed citations

20.

Beslija, S., et al.. (2004). [Comparative parameters of myelotoxicity in patients treated with simultaneous chemotherapy and radiotherapy or only radiotherapy].. PubMed. 58(1). 19–21. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact